Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Somatostatin-28 does not regulate islet function in the dog.

L J Klaff1, B E Dunning, G J Taborsky

  • 1Department of Medicine, Pacific Medical Center, Seattle, Washington 98144.

Endocrinology
|December 1, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The search for the mechanism of early sympathetic islet neuropathy in autoimmune diabetes.

Diabetes, obesity & metabolism·2014
Same author

Rosiglitazone treatment does not decrease amyloid deposition in transplanted islets from transgenic mice expressing human islet amyloid polypeptide.

Transplantation proceedings·2012
Same author

Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans.

Diabetes, obesity & metabolism·2011
Same author

Initiating insulin therapy in elderly patients with Type 2 diabetes: efficacy and safety of lispro mix 25 vs. basal insulin combined with oral glucose-lowering agents.

Diabetic medicine : a journal of the British Diabetic Association·2009
Same author

Loss of islet sympathetic nerves and impairment of glucagon secretion in the NOD mouse: relationship to invasive insulitis.

Diabetologia·2009
Same author

Effect of vildagliptin on glucagon concentration during meals in patients with type 1 diabetes.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme·2008
Same journal

Loss of the calorie restriction response protein DEPP1 worsens diet-induced obesity.

Endocrinology·2026
Same journal

Long Non-Coding RNAs Mediate Endocrine Signaling and Resistance in Prostate Cancer.

Endocrinology·2026
Same journal

Repeated Chemogenetic Activation of C1 Catecholamine Neurons Reduces Subsequent Glucoprivic Responses and Mimics HAAF.

Endocrinology·2026
Same journal

Postnatal exposure to maternal hypothyroidism leads to developmental delay and metabolic dysregulations in male mice.

Endocrinology·2026
Same journal

Discovery proteomics identification of factors contributing to gonadotropin β expression.

Endocrinology·2026
Same journal

3D genome architecture and epigenetic regulation of lineage identity in advanced prostate cancer.

Endocrinology·2026
See all related articles

Somatostatin-28 (S-28) is less potent than somatostatin-14 (S-14) at inhibiting insulin secretion in dogs. Post-meal S-28 levels are insufficient to suppress insulin release, challenging its role as a primary gut hormone regulator.

Area of Science:

  • Endocrinology
  • Gastroenterology
  • Metabolic Regulation

Background:

  • Somatostatin-28 (S-28) is proposed as a gut hormone regulating insulin secretion.
  • Evidence includes S-28's presence in intestinal D-cells and its release post-meal.
  • Previous reports suggested S-28 is a more potent inhibitor of insulin secretion than somatostatin-14 (S-14).

Purpose of the Study:

  • To critically evaluate the hypothesis that S-28 is a gut hormone regulating insulin secretion.
  • To compare the potencies of S-28 and S-14 in inhibiting insulin and glucagon secretion in vivo.
  • To compare post-meal endogenous somatostatin-like immunoreactivity (SLI) levels with infused S-28 concentrations required for insulin inhibition.

Main Methods:

  • Infusion of S-28 and S-14 into dogs to measure circulating somatostatin-like immunoreactivity (SLI).

Related Experiment Videos

  • Measurement of immunoreactive insulin (IRI) and immunoreactive glucagon (IRG) output during infusions.
  • Analysis of endogenous SLI levels in arterial plasma after a mixed meal.

    • Main Results:

    • Infusion of S-28 raised SLI levels but showed significantly less inhibition of IRI secretion compared to S-14 at comparable SLI increments.
    • High-dose S-28 infusion inhibited pancreatic SLI output, but not glucagon secretion.
    • Post-meal endogenous SLI levels were substantially lower than those achieved with infused S-28 that inhibited insulin secretion.

    Conclusions:

    • S-28 is significantly less potent than S-14 in inhibiting insulin secretion in the dog model.
    • Post-meal circulating S-28 levels are unlikely to be sufficient to suppress insulin secretion.
    • The hypothesis of S-28 acting as a primary gut hormone regulator of insulin secretion is not supported by these findings.